The IV Therapy Academy

A large Phase 3 trial has added weight to the case for retatrutide as a possible future treatment for adults living with both obesity and type 2 diabetes. The study, published in The Lancet on 29 September 2026, reported substantial average weight loss over 80 weeks in people receiving weekly retatrutide injections. Blood glucose control also improved, which matters because weight and glucose management are closely linked in type 2 diabetes care. The results are promising, bu

Over the past 12 months, a growing number of people using GLP-1 medications such as Semaglutide, Tirzepatide and newer therapies like Retatrutide have reported something unexpected. Not just reduced hunger. Not just weight loss. But a feeling of becoming emotionally "flat," less interested in things they once enjoyed, or simply feeling like they "don't care" as much as they used to. While these medications have transformed the treatment of obesity and metabolic disease, under